Compare BioNTech SE - ADR (BNTX) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Open Text Corporation — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Open Text Corporation trades at $22.53 (market cap $5.40B). The key difference: BioNTech SE - ADR is far larger — about 4.2× Open Text Corporation's market cap, and Open Text Corporation pays a 4.9% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | OTEX | |
|---|---|---|
Market Cap | $22.86B | $5.40B |
Sector | Health | Technology |
52-Week High | $119.34 | $39.69 |
52-Week Low | $83.89 | $20.01 |
Enterprise Value | $6.53B | $10.56B |
Dividend Yield | — | 4.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
OpenText (OTEX) trades at $23.57, up 2.43% on the day, with a bullish technical signal from moving averages. The company shows strong profitability with a 73.06% gross margin and has beaten earnings estimates for the last three quarters. Recent strategic moves include a $105 million investment in European AI and cloud expansion and the divestiture of the non-core Vertica business.
The outlook is positive, supported by a consensus analyst price target of $29.75, implying significant upside. Key opportunities include margin expansion and AI-driven growth, while risks involve integration of strategic shifts and competitive pressures in the enterprise software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
